Observational, Non-interventional, Multicenter Study Aimed at Collecting Prospective Data Related to Study Safety and Effectiveness in Real Clinical Practice in Patients With CD30+ Lymphoma (BRAVE Study)
Latest Information Update: 13 Jul 2026
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Lymphoma
- Focus Adverse reactions
- Acronyms BRAVE
- Sponsors Takeda
Most Recent Events
- 07 Jul 2026 Actual primary completion date changed from 18 Jun 2026 to 26 Jun 2026.
- 30 Jun 2026 Status changed from active, no longer recruiting to completed.
- 27 Jan 2025 Planned End Date changed from 1 Jan 2025 to 19 Jun 2026.